middle.news
Imugene Doses First Patient in BTKi Combo Cohort of Azer-cel Trial
9:41am on Thursday 28th of May, 2026 AEST
•
Healthcare
Read Story
Imugene Doses First Patient in BTKi Combo Cohort of Azer-cel Trial
9:41am on Thursday 28th of May, 2026 AEST
Key Points
First patient dosed in BTKi combination cohort
Focus on BTKi-relapsed mantle cell lymphoma
Azer-cel combined with BTKi to enhance efficacy
Trial expansion across US and Australian sites
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE